Advisor Group Holdings, Inc. Cardiff Oncology, Inc. Transaction History

Advisor Group Holdings, Inc.

$42.2 Billion
Q3 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,400 shares of CRDF stock, worth $3,513. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,400

Previous 1,400 -0.0%

Holding current value

$3,513

Previous $3,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.22 - $5.89 $976 - $2,591	-440 Reduced 23.91%	1,400 $3,000
Q4 2023 Feb 12, 2024	BUY	$0.96 - $1.55 $960 - $1,550	1,000 Added 119.05%	1,840 $2,000
Q3 2023 Nov 13, 2023	SELL	$1.38 - $2.18 $1,000 - $1,580	-725 Reduced 46.33%	840 $1,000
Q1 2023 May 12, 2023	BUY	$1.45 - $2.09 $411 - $593	284 Added 22.17%	1,565 $2,000
Q4 2022 Feb 10, 2023	SELL	$1.22 - $1.66 $159 - $217	-131 Reduced 9.28%	1,281 $1,000
Q3 2022 Nov 14, 2022	SELL	$1.54 - $3.21 $408 - $850	-265 Reduced 15.8%	1,412 $3,000
Q2 2022 Aug 10, 2022	SELL	$1.17 - $2.61 $621 - $1,385	-531 Reduced 24.05%	1,677 $4,000
Q1 2022 May 04, 2022	SELL	$2.11 - $7.25 $561 - $1,928	-266 Reduced 10.75%	2,208 $5,000
Q3 2021 Nov 05, 2021	SELL	$5.01 - $7.58 $596 - $902	-119 Reduced 4.59%	2,474 $17,000
Q2 2021 Aug 02, 2021	SELL	$6.65 - $10.04 $72,857 - $109,998	-10,956 Reduced 80.86%	2,593 $18,000
Q1 2021 May 13, 2021	BUY	$9.1 - $19.57 $103,357 - $222,276	11,358 Added 518.39%	13,549 $125,000
Q4 2020 Feb 10, 2021	SELL	$12.02 - $24.71 $15,734 - $32,345	-1,309 Reduced 37.4%	2,191 $39,000
Q3 2020 Nov 12, 2020	BUY	$4.25 - $14.19 $14,875 - $49,665	3,500 New	3,500 $50,000

Others Institutions Holding CRDF

# of Institutions

Shares Held

12.3M

Call Options Held

813K

Put Options Held

91.1K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $109M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Cardiff Oncology, Inc. Transaction History